The risk score of each sample was calculated as follows: Risk score = 0.287637545 × IFIT5 + (-0.40877001) × MRPL14 + 0.623197758 × MRPL21+ 0.697194958× MRPL39 + 0.39822836 × MVP + 0.545513896 × PUSL1, and 161 AML patients in the training set were divided into high and low risk groups by the median risk score (1.037), including 80 samples in the high-risk group and 81 samples in the low-risk group. The gene discussed is MRPL21; the disease is acute myeloid leukemia.